PlantoSys receives CE biostimulant mark for products SilicaPower and SalicylPure
by Annelies Ribbink24 February 20251 min read
PlantoSys, a leader in natural-based biostimulants and fertilisers, has recently received the CE mark for two of its biostimulants: SilicaPower (silicon-based) and SalicylPure (willow bark extract-based). These products have been successfully used for years by farmers and growers in both agriculture and horticulture.
To obtain the CE mark, extensive research was conducted on eight CEN-standardised crop groups, with results rigorously assessed by the ‘notified body,’ an accredited control body by the Dutch Food and Consumer Product Safety Authority (NVWA).
The CE mark is a significant milestone for PlantoSys, facilitating easier access to the European market and, more importantly, assuring users of the high quality of the products.
According to Alwin Scholten, managing director of PlantoSys, obtaining the CE mark is a costly and time-consuming process. However, it underscores the scientific validation of their biostimulants and the careful work behind them. “This process demonstrates that our motto, 'driven by research, proven in practice,' is not just a slogan. Customers can trust that our products are not only practically effective but also scientifically validated. The CE mark for these biostimulants is a key milestone for us," Scholten concluded.
The CE mark is a significant milestone for PlantoSys, facilitating easier access to the European market and, more importantly, assuring users of the high quality of the products.
According to Alwin Scholten, managing director of PlantoSys, obtaining the CE mark is a costly and time-consuming process. However, it underscores the scientific validation of their biostimulants and the careful work behind them. “This process demonstrates that our motto, 'driven by research, proven in practice,' is not just a slogan. Customers can trust that our products are not only practically effective but also scientifically validated. The CE mark for these biostimulants is a key milestone for us," Scholten concluded.
